Cargando…
Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial
Objective: In this study, we investigated the efficacy and safety of remdesivir and tocilizumab combination therapy against dexamethasone for the management of severe COVID-19 patients. Methods: This was a multicenter study. Cases were randomly chosen and divided into two groups using an odd–even ra...
Autores principales: | Mohiuddin Chowdhury, Abu Taiub Mohammed, Kamal, Aktar, Abbas, Kafil Uddin, Talukder, Shubhashis, Karim, Md Rezaul, Ali, Md. Ahsan, Nuruzzaman, Md., Li, Yarui, He, Shuixiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017992/ https://www.ncbi.nlm.nih.gov/pubmed/35450050 http://dx.doi.org/10.3389/fphar.2022.690726 |
Ejemplares similares
-
Role of H(2 )receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial
por: Mohiuddin Chowdhury, Abu Taiub Mohammed, et al.
Publicado: (2022) -
Clinical Characteristics and the Long-Term Post-recovery Manifestations of the COVID-19 Patients—A Prospective Multicenter Cross-Sectional Study
por: Mohiuddin Chowdhury, Abu Taiub Mohammed, et al.
Publicado: (2021) -
Dexamethasone/remdesivir/tocilizumab: Various toxicities: case report
Publicado: (2022) -
Dexamethasone/remdesivir/tocilizumab: Lack of efficacy: case report
Publicado: (2022) -
LncRNA SNAI3-AS1 promotes PEG10-mediated proliferation and metastasis via decoying of miR-27a-3p and miR-34a-5p in hepatocellular carcinoma
por: Li, Yarui, et al.
Publicado: (2020)